Clinical Metabolomics Inc.
Sharpening clinical trials with metabolomics
This article was originally published in Start Up
Pharma has had trouble developing therapeutics for diabetic kidney disease because of its slow disease process – it can take months or years to demonstrate an improvement in kidney function in response to a drug. Researchers at Clinical Metabolomics Inc. (doing business as ClinMet) think their technology for monitoring kidney function through metabolites found in the urine can speed clinical trials by identifying signs of kidney improvement, and the research also has led to a new insight into the underlying causes of DKD that could lead to new therapies.